AI-generated analysis. Always verify with the original filing.
Turn Therapeutics Inc. reported full year 2025 financial results with net loss of $3.2 million, secured up to $25 million growth capital, and provided updates on GX-03 Phase 2 trial and corporate developments.
Event Type
Disclosure
Mandatory
Variant
8-K
of this Current Report on Form 8-K and the Press Release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securiti
Financial Statements and Exhibits.** **(d) Exhibits** | Exhibit No. | | Description | |---|---|---| | 99.1 | | Press Release, dated March 31, 2026 | | 104 | | C
| Metric | Value | Basis |
|---|---|---|
| General and Administrative Expenses | $5.6M | GAAP |
| Research and Development Expenses | $265.6K | GAAP |
| Total Operating Expenses | $5.9M | GAAP |
| Loss from Operations | $-5.9M | GAAP |
| Net Loss | $-3.2M | GAAP |
| Basic and Diluted Net Loss per Common Share | $-0.12 | GAAP |
Dr. Robert Redfield
Provide strategic guidance on GX-03 development and regulatory path
Martin Dewhurst
Support long-term growth and strategic development
Debt / Financing